Angola vs Yemen: Death rate from Parkinson's disease
Angola
1.07 deaths per 100,000 people
in 2021
Yemen
1.07 deaths per 100,000 people
in 2021
Angola rank
167th
Yemen rank
167th
Death rate from Parkinson's disease over time
- Angola
- Yemen
How they compare
Angola currently reports 1.07 deaths per 100,000 people against 1.07 deaths per 100,000 people in Yemen, a difference of 0 deaths per 100,000 people.
Across all 22 years both countries report, Yemen has been ahead every year.
Angola ranks 167th and Yemen ranks 167th of 194 countries.
Yemen has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Angola | Yemen | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.881 deaths per 100,000 people | 1.03 deaths per 100,000 people | 0.151 deaths per 100,000 people | Yemen |
| 2010s | 0.946 deaths per 100,000 people | 1.1 deaths per 100,000 people | 0.156 deaths per 100,000 people | Yemen |
| 2020s | 1.08 deaths per 100,000 people | 1.12 deaths per 100,000 people | 0.035 deaths per 100,000 people | Yemen |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher death rate from parkinson's disease, Angola or Yemen?
- Angola, at 1.07 deaths per 100,000 people against 1.07 deaths per 100,000 people in Yemen as of 2021.
- What is the difference in death rate from parkinson's disease between Angola and Yemen?
- 0 deaths per 100,000 people, with Angola ahead.
- How many years of comparable data are there for Angola and Yemen?
- 22 years are reported by both, from 2000 to 2021.
- How do Angola and Yemen rank globally for death rate from parkinson's disease?
- Angola ranks 167th and Yemen ranks 167th of 194 countries.
- Where does this data come from?
- World Health Organization (2024) β with major processing by Our World in Data, published as Death rate from Parkinson's disease. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated number of deaths from parkinson disease in both sexes, per 100,000 people.